Premium
Combination chemotherapy as single modality therapy for stage IE and IIE thyroid lymphoma
Author(s) -
Leedman Peter J.,
Sheridan William P.,
Downey William F.,
Fox Richard M.,
Martin F. Ian R.
Publication year - 1990
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1990.tb124428.x
Subject(s) - medicine , vincristine , cyclophosphamide , chemotherapy , thyroid lymphoma , prednisolone , bleomycin , combination chemotherapy , stage (stratigraphy) , surgery , lymphoma , methotrexate , thyroid , oncology , thyroiditis , paleontology , biology
Three women presented with malignant thyroid lymphoma (stage IE and IIE) that was associated with Hashimoto's thyroiditis. Each patient was treated with combination chemotherapy (two patients received cyclophosphamide/adriamycin/vincristine/prednisolone, one patient received methotrexate/adriamycin/cyclophosphamide/vincristine/prednisolone/bleomycin) as the primary mode of therapy. One patient underwent incomplete excisional surgery and received chemotherapy. A complete clinical and radiological remission was achieved in all patients, in spite of evidence of extensive extrathyroidal invasion in two patients. The chemotherapy was well‐tolerated, producing minimal toxicity. All the patients are alive and remain free of tumour recurrence 26 to more than 38 months after diagnosis. These results suggest that combination chemotherapy can be employed successfully as a single modality treatment for stage IE and IIE thyroid lymphomas, even when significant extrathyroidal invasion is present. The treatment of thyroid lymphoma is reviewed with emphasis on the potential role for chemotherapy as the primary modality.